)
Chris Francis, PhD
SVP, Corporate Development and Head of Emerging Areas
Wave Life Sciences
Since joining Wave in April 2014, Dr. Chris Francis has contributed to Wave’s private and public financings and led the formation of external research collaborations, including the ongoing collaborations with Takeda and GSK. Chris is also a co-inventor of Wave platform-related intellectual property. In addition to his role at Wave, Chris has served as a Member of the Investment Review Committee for WEHI Ventures in Australia since 2023. Prior to Wave, Chris led strategy, business development and scientific operations for GSK’s immuno-oncology unit; licensing and contributing to the early development of multiple programs currently in clinical trials. He began his career in healthcare private equity with Two River LLC and pharmaceutical pricing reimbursement consulting with IMS Health. Chris received undergraduate and graduate degrees in biochemistry and biophysics from the University of Melbourne, and doctoral training at the University of Cambridge.
Sessions
-
23-Jun-202632ABBeyond GLP-1s – New Mechanisms and Modalities for Metabolic Disease
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}